September 23, 2025 (15:00) "Exploring the boundaries of nuclear reprogramming" Dr Jose Maria Polo IJC Auditorium + Online Registration here Invited Lectures
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS BLOOD ADV
Corrigendum to "Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study" [Eur. J. Cancer 2025 Aug 26;226:115535. PMID: 40743655] Eur J Cancer
Impact of MICA-129 mismatch on HSCT outcomes: Evidence from a large European cohort and meta-analysis TRANSPL CELL THER
METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis Oncogene
The Josep Carreras Institute and the Hospital del Mar Research Institute strengthen their institutional collaboration August 21, 2025 The Josep Carreras Institute and the Hospital del Mar Research Institute strengthen their institutional collaboration
A new therapy could improve the response to childhood acute lymphoblastic leukaemia August 06, 2025 A new therapy could improve the response to childhood acute lymphoblastic leukaemia
The Josep Carreras Institute promotes the development of mRNA-based therapies for Rett Syndrome in collaboration with Bionure July 30, 2025 The Josep Carreras Institute promotes the development of mRNA-based therapies for Rett Syndrome in collaboration with Bionure
New research programme to tackle childhood leukaemia at the Josep Carreras Institute July 24, 2025 New research programme to tackle childhood leukaemia at the Josep Carreras Institute
The Communication Unit of the Josep Carreras Institute is accredited as a Scientific Culture and Innovation Unit July 23, 2025 The Communication Unit of the Josep Carreras Institute is accredited as a Scientific Culture and Innovation Unit
Epigenetics on demand to tackle inflammatory diseases July 17, 2025 Epigenetics on demand to tackle inflammatory diseases
A new cell therapy for leukaemia shows high efficacy and safety in the laboratory July 07, 2025 A new cell therapy for leukaemia shows high efficacy and safety in the laboratory